Skip to main content
Premium Trial:

Request an Annual Quote

BD's Q1 Biosciences Sales Stagnant, Dx Revenues up 10%

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its first-quarter revenues swelled 12 percent year over year, or 9 percent on a currency-neutral basis, driven largely by a 10 percent spike in its diagnostics sales, while revenues from the BD Biosciences segment were flat.

The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.9 billion for the three-month period ended December 31, up from revenues of $1.7 billion in the first quarter of 2009.

The BD Biosciences business segment had revenues of $302.7 million for the quarter, and was nearly unchanged from its revenues of $302.5 million for Q1 2009. That segment's Cell Analysis revenues were up 1 percent at $231.3 million compared with $229.5 million, and its Discovery Labware business fell 2 percent to $71.3 million from $73 million in the year-ago period

The BD Diagnostics segment had revenues of $595.5 million, a 10 percent increase from revenues of $540.2 million for the second quarter of 2009. The BD Diagnostics segment's Pre-analytical Systems business saw in increase of 8 percent to $300.2 million from $278.2 million. The Diagnostics Systems business rose to $295.3 million from $262 million, an increase of 13 percent.

BD's net income for Q1 was $316.4 million, or $1.30 per share, from $312.1 million, or $1.26 per share, for Q1 2009. Its R&D expenses increased roughly 3 percent to $100.3 million from $97.3 million, while its SG&A spending rose 11 percent to $450.9 million from $406 million.

The firm expects to report growth of around 7 percent for full-year 2010, compared with its earlier guidance of around 6 percent.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.